Biography: Life Sciences

Paul E Kalb, MD heads the firm's national healthcare group and is a member of the firm's executive committee. He represents many of the world's leading drug, biotech and device manufacturers as well as hospitals and other institutional healthcare providers in criminal, civil, and administrative enforcement actions and related civil litigation involving healthcare fraud and abuse and off-label promotion. In that capacity, he has successfully led teams that defended numerous matters and negotiated a number of ground-breaking settlement agreements and corporate integrity agreements. Representative clients in such matters that are public include Apria Healthcare Group, Inc, AstraZeneca, Inc, the Bayer Corporation, Eli Lilly and Company, Genentech, Inc, Magellan Health Services, Inc, Novo-Nordisk, Inc, Schering-Plough Corporation and Sun Healthcare Group, Inc. He also counsels manufacturers, providers, consultants, lenders and investors on enforcement issues.

Dr Kalb is a graduate of Yale Law School, where he was an editor of the Yale Law Journal. He received his MD degree, magna cum laude, from the Boston University School of Medicine, completed his residency in Internal Medicine at the New York Hospital-Cornell Medical Center, and served as an attending physician at the Memorial Sloan-Kettering Cancer Center. He was a visiting lecturer at Yale College in Medicine, Law and Public Policy. He is an author, along with Robert Fabrikant, Mark Hopson and Pamela Bucy, of Health Care Fraud: Enforcement and Compliance and the author (or co-author) of numerous articles in legal, medical, and industry publications. He speaks regularly at industry conferences and has also lectured on fraud and abuse issues at the Justice Department's national training center.

On several occasions, Dr Kalb has been named by BTI Consulting, on the basis of a survey of Fortune 1000 companies, as a member of the BTI Client Service All-Star Team for law firms. He was given the highest ranking among US lawyers in the 'investigations' category in PLC's 2009/10, 2008/09, 2007/08 and 2006/07 surveys of leading life science lawyers worldwide and has also been named as a leading lawyer in PLC's worldwide dispute resolution survey. He is listed as a leader in the field of healthcare law by Chambers USA, was named by Washingtonian magazine as one of the 'Top Lawyers in Washington' and was recognised in the 2011 edition of The Best Lawyers in America in healthcare law.